Challenges Related to Antimalarial Abuse in Coronavirus Disease-2019 Treatment in the Democratic Republic of Congo

Crossmark: check for updates

Authors

  • Anselme Manyong Chief of Party, Impact Malaria (PMI) DRC Chez Medical Care Development International-MCDI, Kinshasa, Democratic Republic of the Congo
  • Ange Landela M&E Officer, PMI Impact Malaria, DRC Technical Diagnostics, Democratic Republic of the Congo

DOI:

https://doi.org/10.17140/EPOJ-5-121

Keywords:

Malaria, Covid-19, Morbidity and mortality, Abuse antimalarial, Drug resistance

Abstract

Malaria is endemic to many African countries and geographies and remains the leading cause of morbidity and mortality on the continent. Ongoing efforts by health authorities to reverse the scale of malaria are often faced to the challenges of drug resistance often generated by therapeutic abuses relating to self-medication, sub-therapeutic under dosages and poor storage and handling of drugs throughout the pharmacy supply chain system.

References

Stop Coronavirus COVID-19 RDC. Web site. https://www. stopcoronavirusrdc.info/. Accessed July 29, 2020.

Drug resistance and response. Web site. https://www.who.int/ malaria/areas/drug_resistance/en/. Accessed July 29, 2020.

Google Scholar. Web site. https://scholar.google.com/scholar ?q=DRC+Demographic+and+Health+Survey,+DHS+2004&h l=en&as_sdt=0&as_vis=1&oi=scholart. Accessed July 29, 2020.

Annales Africanies de Medecine. Web site. https://anafrimed. net/quel-systeme-de-securite-sociale-pour-la-rdc-assurance-mala-die-mutuelles-assurances-privees/. Accessed July 29, 2020. Commentary | Volume 5 | Issue 1|

Downloads

Published

2020-11-30

How to Cite

Anselme Manyong, & Ange Landela. (2020). Challenges Related to Antimalarial Abuse in Coronavirus Disease-2019 Treatment in the Democratic Republic of Congo. Epidemiology, 5(1), 17–18. https://doi.org/10.17140/EPOJ-5-121

Issue

Vol. 5 No. 1 (2020): Volume 5 Issue 1 2020

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Epidemiology (EOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.